« Previous
Next »
Titles
- Rate of uninsured infants and toddlers on the rise1
- Recognition and withdrawal of voluntary consensus standards: guidance for industry and Food and Drug Administration staff1
- Recommendations for clinical laboratory improvement amendments of 1988 (CLIA) waiver applications for manufacturers of in vitro diagnostic devices: guidance for industry and Food and Drug Administration staff1
- Recommendations for dual 510(k) and CLIA waiver by application studies: guidance for industry and Food and Drug Administration staff1
- Recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components1
- Recovery with limited progress: impact of California Proposition 209 on racial/ethnic diversity of California medical school matriculants, 1990 to 20191
- Redistribution of federal funding across states due to the financing of Medicaid and CHIP1
- Referencing approved drug products in ANDA submissions2
- Registered nurse and advanced practice registered nurse workforce and education in California1
- Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use : guidance for industry and Food and Drug Administration staff1
- Regulatory considerations for microneedling products: guidance for industry and Food and Drug Administration staff1
- Report on residents1
- Requesting FDA feedback on combination products: guidance for industry and FDA staff1
- Research identifies opportunities to improve person-centered care for substance use disorder1
- Resuming normal drug and biologics manufacturing operations during the COVID-19 public health emergency1
- Review timelines for applicant responses to complete response letters when a facility assessment is needed during the COVID-19 public health emergency1
- Revised CPS estimates show less high burden medical spending1
- Revised recommendations for reducing the risk of human immunodeficiency virus transmission by blood and blood products1
- Revised recommendations to reduce the risk of transfusion-transmitted malaria1
- Risk evaluation and mitigation strategies: modifications and revisions1